Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide + Hydroxychloroquine vs Hydroxychloroquine in COVID-19
NCT04341493Phase 4Terminated
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nitazoxanide in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Mechanical ventilation requirement at 2 weeks. Started Apr 2020; status: terminated.
02
Drugs
nitazoxanide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04341493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341493.